中文摘要：

目的对人类白细胞抗原A2分子（HLA-A2）限制性细胞毒性T淋巴细胞（CTL）表位HPV18E77-15进行氨基酸置换修饰,并探讨修饰后多肽的免疫原性。方法根据量化模体方案,比较置换后的多肽与HLA-A2分子的结合系数,采用标准Fmoc方案合成并纯化多肽、细胞毒实验（51Cr释放法）,观察多肽是否能够诱导特异性CTLs。结果修饰肽TLQDIVLHV符合HLA-A2分子限制性细胞毒性T细胞的表位要求,具有特异性细胞毒性T细胞诱导活性。结论修饰肽TLQDIVLHV具有更好的结合力和较强的抗原性,可以作为高危型人乳头瘤病毒（HPV）感染治疗性肽疫苗分子设计的候选表位。

英文摘要：

Objective To investigate the immunogenicity of peptide modified by amino acid substitution for the CTL epitope HPV18E77-15 restricted by HLA-A2.Methods The affinity of the substituted peptide was compared by quantitative method.Peptides were synthesized and purified by standard Fmoc assay.51Cr release assay was used to determine their abilities of inducing the generation of specific CTLs.Results The modified peptide TLQDIVLHV met the requirements of HLA-A2-restricted CTL epitopes and had the ability of inducing the generation of specific CTLs.Conclusions The modified peptide TLQDIVLHV has better antigenicity and affinity to HLA-A2,and can be used as one of the HLA-A2-restricted candidate epitopes for therapeutic peptide vaccine against HPV infection.